Evidence map›Paper›PMID 37645153›Full record

ReviewOpen research Europe2021

Safeguarding COVID-19 and cancer management: drug design and therapeutic approach.

Nanasaheb Thorat, Sabrina Pricl, Abdul K Parchur, Sandeep B Somvanshi, Qifei Li, Sachin Umrao, Helen Townley

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Open research Europe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 5 countries.

Nanasaheb ThoratNuffield Department of Women's & Reproductive Health, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.ORCID https://orcid.org/0000-0001-6343-527X
Sabrina PriclMolBNL@UniTS-DEA, University of Trieste, Piazzale Europa 1, Trieste, 34127, Italy.ORCID https://orcid.org/0000-0001-8380-4474
Abdul K ParchurRadiation Oncology, Froedtert Hospital & Medical College of Wisconsin, Medical College of Wisconsin, Wisconsin, USA.ORCID https://orcid.org/0000-0002-2417-9848
Sandeep B SomvanshiSchool of Materials Engineering, Purdue University, West Stadium Avenue, West Lafayette, USA.
Qifei LiDivision of Newborn Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Sachin UmraoDepartment of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, USA.
Helen TownleyNuffield Department of Women's & Reproductive Health, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.
John Radcliffe Hospital · GBBoston Children's Hospital · USFroedtert Hospital · USPurdue University West Lafayette · USUniversity of Trieste · ITYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical cohort studies have highlighted that there is a three-fold greater SARS-Cov-2 infection risk in cancer patients, and overall mortality in individuals with tumours is increased by 41% with respect to general COVID-19 patients. Thus, access to therapeutics and intensive care is compromised for people with both diseases (comorbidity) and there is risk of delayed access to diagnosis. This comorbidity has resulted in extensive burden on the treatment of patients and health care system across the globe; moreover, mortality of hospitalized patients with comorbidity is reported to be 30% higher than for individuals affected by either disease. In this data-driven review, we aim specifically to address drug discoveries and clinical data of cancer management during the COVID-19 pandemic. The review will extensively address the treatment of COVID-19/cancer comorbidity; treatment protocols and new drug discoveries, including the description of drugs currently available in clinical settings; demographic features; and COVID-19 outcomes in cancer patients worldwide.

Indexed as

anticancer drugsantiviral therapiesCancerCovid 19

Identifiers

PMID37645153
PMCPMC10445946
OpenAlexW3179505692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.